Diabetic patients challenge insulin makers February 06, 2017 By Christine Blank In the latest flap over the high cost of drugs, diabetes patients filed a class-action lawsuit against insulin makers. New diabetes combo drug available soon December 19, 2016 By Christine Blank A new combination drug for type 2 diabetes will available in the US in the coming months. New drug indication could net more than $1 billion December 05, 2016 By Christine Blank FDA’s approval of a new indication for empagliflozin (Jardiance, Eli Lilly and Boehringer Ingelheim) could net the pharmaceutical manufacturers more than $1 billion. Insulin makers accused of price collusion November 07, 2016 By Christine Blank U.S. congressmen last week asked the Department of Justice and the Federal Trade Commission to investigate three insulin makers for price collusion—the latest in concerns over insulin prices. High-dose insulin pen hits market January 26, 2016 By Christine Blank Eli Lilly & Company finally releases a high-dose insulin pen, which will help cut down on medication errors associated with the U-100 Humulin insulin pens. Drugmakers debate pricing, legislation January 12, 2016 By Christine Blank Pharmaceutical companies are battling state legislation that would require state programs such as Medicaid to pay no more than other Federal government programs for drugs. First “follow-on” insulin glargine product approved to treat diabetes December 21, 2015 By Erin Bastick FDA approved insulin glargine injection (Basaglar, Eli Lilly) to improve glycemic control in patients with diabetes mellitus. New rheumatoid arthritis therapies are coming December 19, 2015 By Tracey Walker Four new drugs and a biosimilar should be on your radar. New psoriasis therapies must demonstrate value December 01, 2015 By Tracey Walker Psoriasis affects a small percentage of the population but price increases for drug treatments have outpaced the Consumer Price Index. FDA approves Portrazza for specific type of lung cancer December 01, 2015 By Christine Blank In its latest round of cancer drug approvals, the FDA last week approved Portrazza (necitumumab) in combination with two forms of chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC).